{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:38:30Z","timestamp":1780922310140,"version":"3.54.1"},"reference-count":31,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH"},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"crossref","award":["TL1 TR001871"],"award-info":[{"award-number":["TL1 TR001871"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"crossref","award":["1-19-PDF-131"],"award-info":[{"award-number":["1-19-PDF-131"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001167","name":"Larry L. Hillblom Foundation","doi-asserted-by":"crossref","award":["2022-D-006-SUP"],"award-info":[{"award-number":["2022-D-006-SUP"]}],"id":[{"id":"10.13039\/100001167","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH"},{"name":"NCI","award":["K99CA246061"],"award-info":[{"award-number":["K99CA246061"]}]},{"name":"NIH"},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"crossref","award":["K24 AR074534"],"award-info":[{"award-number":["K24 AR074534"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH"},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"crossref","award":["P30 AR070155"],"award-info":[{"award-number":["P30 AR070155"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH"},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["T32 DK007058"],"award-info":[{"award-number":["T32 DK007058"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation","doi-asserted-by":"crossref","award":["3-APF-2019-753-A-N"],"award-info":[{"award-number":["3-APF-2019-753-A-N"]}],"id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH","award":["K12 CA215110"],"award-info":[{"award-number":["K12 CA215110"]}]},{"DOI":"10.13039\/100015334","name":"Endocrine Fellows Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015334","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH"},{"name":"NCI","award":["R01 CA227473"],"award-info":[{"award-number":["R01 CA227473"]}]},{"DOI":"10.13039\/100014547","name":"Parker Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"crossref"}]},{"name":"JDRF"},{"name":"Helmsley Foundation"},{"name":"NIH"},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["K08 DK129829-01"],"award-info":[{"award-number":["K08 DK129829-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Hypophysitis is a known immune-related adverse event (irAE) of immune checkpoint inhibitors (CPIs), commonly associated with CTLA-4 inhibitors and less often with PD-1\/PD-L1 inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to determine clinical, imaging, and HLA characteristics of CPI-induced hypophysitis (CPI-hypophysitis).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined the clinical and biochemical characteristics, magnetic resonance imaging (MRI) of the pituitary, and association with HLA type in patients with CPI-hypophysitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-nine patients were identified. Mean age was 61.3 years, 61.2% were men, 81.6% were Caucasian, 38.8% had melanoma, and 44.5% received PD-1\/PD-L1 inhibitor monotherapy while the remainder received CTLA-4 inhibitor monotherapy or CTLA-4\/PD-1 inhibitor combination therapy. A comparison of CTLA-4 inhibitor exposure vs PD-1\/PD-L1 inhibitor monotherapy revealed faster time to CPI-hypophysitis (median 84 vs 185 days, P &amp;lt; .01) and abnormal pituitary appearance on MRI (odds ratio 7.00, P = .03). We observed effect modification by sex in the association between CPI type and time to CPI-hypophysitis. In particular, anti-CTLA-4 exposed men had a shorter time to onset than women. MRI changes of the pituitary were most common at the time of hypophysitis diagnosis (55.6% enlarged, 37.0% normal, 7.4% empty or partially empty) but persisted in follow-up (23.8% enlarged, 57.1% normal, 19.1% empty or partially empty). HLA typing was done on 55 subjects; HLA type DQ0602 was over-represented in CPI-hypophysitis relative to the Caucasian American population (39.4% vs 21.5%, P = 0.01) and CPI population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The association of CPI-hypophysitis with HLA DQ0602 suggests a genetic risk for its development. The clinical phenotype of hypophysitis appears heterogenous, with differences in timing of onset, changes in thyroid function tests, MRI changes, and possibly sex related to CPI type. These factors may play an important role in our mechanistic understanding of CPI-hypophysitis.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jendso\/bvad012","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T16:11:26Z","timestamp":1675699886000},"source":"Crossref","is-referenced-by-count":26,"title":["Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor\u2013Induced Hypophysitis"],"prefix":"10.1210","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-4368","authenticated-orcid":false,"given":"Zoe","family":"Quandt","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"},{"name":"Diabetes Center, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Villanueva-Meyer","sequence":"additional","affiliation":[{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Coupe","sequence":"additional","affiliation":[{"name":"Diabetes Center, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arabella","family":"Young","sequence":"additional","affiliation":[{"name":"Diabetes Center, University of California, San Francisco , San Francisco, CA 94122 , USA"},{"name":"Huntsman Cancer Institute, University of Utah Health Sciences Center , Salt Lake City, UT 84112 , USA"},{"name":"Department of Pathology, University of Utah School of Medicine , Salt Lake City, UT 84112 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hye","family":"Kang","sequence":"additional","affiliation":[{"name":"Diabetes Center, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-4094","authenticated-orcid":false,"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"},{"name":"Division of Rheumatology, Department of Medicine, Zuckerberg San Francisco General Hospital , San Francisco, CA 94110 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Schmajuk","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"},{"name":"Division of Rheumatology, Department of Medicine, Zuckerberg San Francisco General Hospital , San Francisco, CA 94110 , USA"},{"name":"Division of Rheumatology, Department of Medicine, San Francisco VA Medical Center , San Francisco, CA 94121 , USA"},{"name":"Philip R. Lee Institute for Health Policy Studies , San Francisco, CA 94158 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Rush","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-2884","authenticated-orcid":false,"given":"Elad","family":"Ziv","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Luisa","family":"Perdigoto","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University , New Haven, CT 06520 , USA"},{"name":"Department of Internal Medicine, Yale University , New Haven, CT 06520 , USA"},{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Yale University , New Haven, CT 06520 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan","family":"Herold","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University , New Haven, CT 06520 , USA"},{"name":"Department of Internal Medicine, Yale University , New Haven, CT 06520 , USA"},{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Yale University , New Haven, CT 06520 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa G","family":"Lechner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine , CA 90095 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen A","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Medical Genetics, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 , USA"},{"name":"Department of Pediatrics, UCLA David Geffen School of Medicine , Los Angeles, CA 90095 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Blake","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bluestone","sequence":"additional","affiliation":[{"name":"Diabetes Center, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"},{"name":"Diabetes Center, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-804X","authenticated-orcid":false,"given":"Umesh","family":"Masharani","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco , San Francisco, CA 94122 , USA"},{"name":"Diabetes Center, University of California, San Francisco , San Francisco, CA 94122 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-med-050219-034237","article-title":"Autoimmune endocrinopathies: an emerging complication of immune checkpoint inhibitors","volume":"72","author":"Quandt","year":"2020","journal-title":"Annu Rev Med"},{"issue":"12","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J Investig Med"},{"key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"836859","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"11","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40842-016-0034-8","article-title":"Hypophysitis: evaluation and management","volume":"2","author":"Faje","year":"2016","journal-title":"Clin Diabetes Endocrinol"},{"issue":"12","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte\u2013associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"6","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"101371","DOI":"10.1016\/j.beem.2019.101371","article-title":"Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation","volume":"33","author":"Gubbi","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jc.2015-2702","article-title":"HLA Markers DQ8 and DR53 are associated with lymphocytic hypophysitis and may aid in differential diagnosis","volume":"100","author":"Heaney","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor\u2013induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"issue":"1","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"8","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"8","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/db20-0038","article-title":"Failed genetic protection: type 1 diabetes in the presence of hla-dqb1*06:02","volume":"69","author":"Simmons","year":"2020","journal-title":"Diabetes"},{"issue":"D1","key":"2023022712204062000_","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2023022712204062000_","article-title":"Spectrum of clinical presentations, imaging findings and HLA types in immune checkpoint inhibitor induced hypophysitis supplemental materials","author":"Quandt","year":"2023","journal-title":"Dryad"},{"issue":"230","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"7","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1073\/pnas.0308458100","article-title":"Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy","volume":"101","author":"Siebold","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023022712204062000_","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0102","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-l1 blockade: insights from four cases","author":"Lupi","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"19419","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database","volume":"9","author":"Garon-Czmil","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"issue":"5-6","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/08820130802205886","article-title":"Autoimmune disease during pregnancy and the microchimerism legacy of pregnancy","volume":"37","author":"Adams Waldorf","year":"2008","journal-title":"Immunol Invest"},{"issue":"1","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.imlet.2014.06.013","article-title":"The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus","volume":"162","author":"La Rocca","year":"2014","journal-title":"Immunol Lett"},{"issue":"3","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","volume":"58","author":"Brilli","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccc.2005.10.001","article-title":"Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies","volume":"22","author":"De Groot","year":"2006","journal-title":"Crit Care Clin"},{"key":"2023022712204062000_","volume-title":"The Non-Thyroidal Illness Syndrome","author":"De Groot","year":"2015"},{"issue":"12","key":"2023022712204062000_","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvad012\/49102992\/bvad012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/4\/bvad012\/49343571\/bvad012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/4\/bvad012\/49343571\/bvad012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:50:21Z","timestamp":1679629821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvad012\/7028662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvad012","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,2,6]]},"article-number":"bvad012"}}